1070716-32-3

Basic information

• Product Name: tert-butyl 4-(4-chlorophenyl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(4-chlorophenyl)piperazine-1-carboxylate
• CAS NO: 1070716-32-3
• Molecular Formula: C₁₅H₂₁ClN₂O₂
• Molecular Weight: 296.79244
• Mol File: 1070716-32-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(4-chlorophenyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-chlorophenyl)piperazine-1-carboxylate(1070716-32-3)
• EPA Substance Registry System: tert-butyl 4-(4-chlorophenyl)piperazine-1-carboxylate(1070716-32-3)

Safety Data

• Hazardous Substances Data: 1070716-32-3(Hazardous Substances Data)

Upstream product

• 637-87-6 1-Chloro-4-iodobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 106-39-8 bromochlorobenzene 

Downstream Products

• 912369-50-7 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine 
• 1268862-38-9 3-(4-(4-chlorophenyl)piperazin-1-yl)-2-phenylquinoxaline-6-carboxylic acid 
• 1268865-29-7 methyl 3-(4-(4-chlorophenyl)piperazin-1-yl)-2-phenylquinoxaline-6-carboxylate 
• 38212-33-8 4-(4-chlorophenyl) piperazine 
• 1070716-60-7 tert-butyl 4-[4-(1-formylheptyl)phenyl]-1-piperazinecarboxylate 

Relevant articles and documents

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies

Whole-cell screening of 20,000 drug-like small molecules led to the identification of nitrofuranyl methylpiperazines as potent anti-TB agents. In the present study, validation followed by medicinal chemistry has been used to explore the structure-activity relationship. Ten compounds demonstrated potent MIC in the range of 0.17-0.0072 μM against H37Rv Mycobacterium tuberculosis (MTB) and were further investigated against nonreplicating and resistant (RifR and MDR) strains of MTB. These compounds were also tested for cytotoxicity. Among the 10 tested compounds, five showed submicromolar to nanomolar potency against nonreplicating and resistant (RifR and MDR) strains of MTB along with a good safety index. Based on their overall in vitro profiles, the solubility and pharmacokinetic properties of five potent compounds were studied, and two analogues, 14f and 16g, were found to have comparatively better solubility than others tested and acceptable pharmacokinetic properties. This study presents the rediscovery of a nitrofuranyl class of compounds with improved aqueous solubility and acceptable oral PK properties, opening a new direction for further development.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.